The NFkB activation domain is 14-amino-acid-long variant of the 9aaTAD

Houser J, Jendruchova K, Knight A and Piskacek M

Biochemical Journal (2023) doi.org/10.1042/BCJ20220605

​

Expansions of tumor reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

Knight A, Piskacek M, Jurajda M, Prochazkova J, Racil Z, Zackova D, Mayer J

Cancer Immunology, Immunotherapy (2022) doi.org/10.1007/s00262-022-03312-3

​

Cryptic inhibitory regions nearby activation domains

Knight A and Piskacek M

Biochimie (2022) doi.org/10.1016/j.biochi.2022.05.004

​

Blocking of EphA2 on endometrial tumor cells reduces susceptibility to Vδ1 gamma-delta T cell-mediated killing

Hudecek R, Kohlova B, Siskova I, Piskacek M, Knight A

Frontiers in Immunology (2021) doi.org/10.3389/fimmu.2021.752646

​

Plasmacytoid dendritic cells in patients with MGUS and Multiple Myeloma

Knight A, Rihova L, Kralova R, Penka M, Adam Z, Pour L, Piskacek M and Hajek R

Journal of Clinical Medicine (2021) doi.org/10.3390/jcm10163717

​

The 9aaTAD activation domains in the four Yamanaka Oct4, Sox2, Myc, and Klf4 transcription factors

Piskacek M, Otasevic T, Repko M, Knight A

Stem Cell Rev and Rep (2021) doi.org/10.1007/s12015-021-10225-8   

Full version on www.biorxiv.org/content/10.1101/2019.12.15.876706v1.full.pdf

​

Universal two-point interaction of mediator KIX with 9aaTAD activation domains

Hofrova A, Lousa P, Kubickova M, Hritz J, Otasevic T, Repko M, Knight A and Piskacek M

Journal of Cellular Biochemistry (2021) doi.org/10.1002/jcb.30075​

​

​​​The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with valines and intron reservoirs

Piskacek M, Havelka M, Jendruchova K, Knight A, Keegan LP

Cellular and Molecular Life Sciences (2019) doi.org/10.1007/s00018-019-03251-w

​

​​​Nuclear Hormone Receptors: ancient 9aaTAD and evolutionally gained NCoA Activation Pathways

Piskacek M, Havelka M, Jendruchova K, Knight A

Journal of Steroid Biochemistry and Molecular Biology (2018) doi.org/10.1016/j.jsbmb.2018.11.008

​

The 9aaTAD is exclusive activation domain in Gal4

Piskacek M, Havelka M, Rezacova M, Knight A

PlosOne (2017) doi.org/10.1371/journal.pone.0169261

​

​​​Gal4 activation domain 9aaTAD could be inactivated by adjacent mini-inhibitory domain

and reactivated by distal re-activation domain

Piskacek M, Havelka M, Rezacova M, Knight A

BioRxiv (2017) doi.org/10.1101/110882

​

The 9aaTAD Transactivation Domains: from Gal4 to p53

Piskacek M, Havelka M, Rezacova M, Knight A

PlosOne (2016) doi.org/10.1371/journal.pone.0162842

​

Shared structural features of the 9aaTAD family in complex with CBP

Piskacek M, Vasku A, Hajek R and Knight A

Molecular BioSystems (2014) doi.org/10.1039/c4mb00672k

​​

CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells.

Knight A, Arnouk H, Britt W, Gillespie GY, Cloud GA, Harkins L, Su Y, Lowdell MW, Lamb LS

PLoS One (2013)​ doi.org/journal.pone.0068729

​

Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.

Knight A, Mackinnon S, Lowdell MW

Cytotherapy (2012)​ doi.org/10.3109/14653249.2012.700766

​

The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation.

Knight A, Madrigal AJ, Grace S, Sivakumaran J, Kottaridis P, Mackinnon S, Travers PJ, Lowdell MW

Blood (2010)​ doi.org/10.1182/blood-2010-01-255166

​

Rsp5 promotes Gene Activation mediated by 9aaTAD Transcription Factors Oaf1 and Gal4

Lipp J, Koranda M, Piskacek M 

Nature Precedings (2009) doi.org/10.1038/npre.2009.3968.1

​

A novel 9-amino-acid transactivation domain in the C-terminal part of Sox18

Sandholzer J, Hoeth M, Piskacek M, Mayer H, de Martin R

Biochem Biophys Res Commun (2007)​ doi.org/10.1016/j.bbrc.2007.06.095

​

9aaTAD Prediction result (2006)

Piskacek M

Nature Precedings (2009)​ doi.org/10.1038/npre.2009.3984.1

​

Nine-amino-acid transactivation domain: Establishment and prediction utilities
Piskacek S, Gregor M, Nemethova M, Grabner M, Kovarik P, Piskacek M
Genomics (2007)​ doi.org/10.1016/j.ygeno.2007.02.003
 

Functional analysis of the Zn(2)Cys(6) transcription factors Oaf1p and Pip2p
Baumgartner U, Hamilton B, Piskacek M, Ruis H, Rottensteiner H
J Biol Chem (1999)​ doi.org/10.1074/jbc.274.32.22208

​

​

Collaboration:

Predicting the function and subcellular location of Caenorhabditis elegans proteins

Gurvitz A, Langer S, Piskacek M, Hamilton B, Ruis H, Hartig A

Yeast (2000)​ doi.org/10.1002/1097-0061(20000930)17:3<188::AID-YEA27>3.0.CO;2-E

 

Conditional Knock-down of the Mitochondrial Magnesium Channel hMrs2

Piskacek M, Zotova L, Zsurka G and Schweyen RJ

Journal of Cellular and Molecular Medicine (2009) doi.org/10.1111/j.1582-4934.2008.00328.x 

​

​Functionally suppressive CD8 T regulatory cells are increased in patients

with multiple myeloma: a cause for immune impairment
Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, Pour L, Hajek R
PLoS One (2012)​ doi.org/10.1371/journal.pone.0049446

​

Do human B-lymphocytes avoid aging until 60 years?

Knight A, Nemec P, Bretzova S, Valkova L, Kolmanova K, Vytopilova R, Havelka M,

Vsianska P, Rihova L, Krejci M and Piskacek M

Oncotarget (2016) doi.org/10.18632/oncotarget.10146

​

The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases

Fafilek B, Balek L, Bosakova MK, Varecha M, Nita A, Gregor T, Gudernova I, Krenova J, Ghosh S, Piskacek M,

Jonatova L, Cernohorsky NH, Zieba JT, Kostas M, Haugsten EM, Wesche J, Erneux C, Trantirek L, Krakow D, Krejci P.

Sci Signal (2018) doi.org/10.1126/scisignal.aap8608

​

Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients.

Hribkova H, Svoboda O, Bartecku E, Zelinkova J, Horinkova J, Lacinova L, Piskacek M, Lipovy B, Provaznik I, Glover JC, Kasparek T, Sun YM.
Front Cell Neurosci. (2022) doi: 10.3389/fncel.2022.830757